Applied Therapeutics to be presented at the 14th International Congress of Innate Errors of Metabolism
NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) – Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against molecular targets validated in high medical need indications not satisfied, announced a symposium and poster presentations at the 14th International Congress on Innate Errors of Metabolism (ICIEM), November 21-23, 2021, in Sydney, Australia.
“We are delighted to present this important data at the ICIEM conference, demonstrating a statistically significant correlation between the level of toxic galactitol and the severity of the disease,” said Shoshana Shendelman, CEO of Applied Therapeutics. In addition, new data on the disease burden in adults with galactosemia demonstrate that the disease continues to progress into adulthood and has a substantial impact on quality of life.
Poster # 504: Progressive worsening of the central nervous system phenotype in children with classical galactosemia on a galactose-restricted diet: a cross-sectional analysis
Poster # 573: Qualitative interviews of adults with classical galactosemia (CG) and their caregivers: burden of disease and challenges of daily living
Poster 574: Galactitol level is a predictor of disease severity in children with classical galactosemia on a galactose-restricted diet
Symposium: Targeting toxic galactitol for the treatment of classical galactosemia
Date and time: November 23, 1:30 p.m. to 2:30 p.m. AEDT
Speakers: Shoshana Shendelman, CEO and Founder of Applied Therapeutics; Riccardo Perfetti, chief medical officer at Applied Therapeutics; Laura Saltonstall, Vice President, Medical Affairs at Applied Therapeutics
About applied therapy
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against molecular targets validated in indications of high unmet medical need. The Company’s lead drug candidate, AT-007, is a novel central nervous system penetrating aldose reductase (ARI) inhibitor for the treatment of rare CNS metabolic diseases including galactosemia, SORD deficiency and PMM2 -CDG. The Company is also developing AT-001, a potent new ARI, for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to pass through the back of the eye when administered orally, for the treatment of diabetic retinopathy, as well as new dual PI3k inhibitors in preclinical development for indications in orphan oncology.
For more information, please visit www.appliedtherapeutics.com and follow the company on Twitter @Applied_Tx.
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for the safe harbor purposes of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this press release regarding management strategy, future operations, outlook, plans and objectives, including words such as “may”, “will”, “expect”, “anticipate”, “plan”, “have” intention ”and similar expressions (as well as other words or expressions referring to future events, conditions or circumstances) are forward-looking statements. The forward-looking statements contained in this press release involve substantial risks and uncertainties which could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and therefore we cannot assure you that our plans, intentions , expectations or strategies will be met or achieved.
These risks and uncertainties include, but are not limited to, factors that could cause actual results to differ from those expressed or implied in the forward-looking statements in this press release. Which is contained therein. Unless otherwise provided by law, we disclaim any intention or obligation to update or revise forward-looking statements, which are only valid as of the date on which they were made, whether as a result of new information, future events or circumstances or otherwise.
(212) 600-1902 or
Applied Therapeutics, Inc.